IP Library Granted Patent US 8,362,211
Granted Patent B2
US 8,362,211 · App. 13/341,860 · Granted Jan 29, 2013

Anti-CD38 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,362,211
App. No.
13/341,860
Granted
Jan 29, 2013
Kind
B2
Abstract

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

Claims (28)

1. The isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:

a) a heavy chain variable region comprising:

i) a first CDR comprising SEQ ID NO:3;

ii) a second CDR comprising SEQ ID NO:4;

iii) a third CDR comprising SEQ ID NO:5; and

b) a light chain variable region comprising:

i) a first CDR comprising SEQ ID NO:6;

ii) a second CDR comprising SEQ ID NO:7;

iii) a third CDR comprising SEQ ID NO:8.

2. The isolated antibody according to claim 1 wherein said heavy chain variable region comprises SEQ ID NO:9.

3. The isolated antibody according to claim 1 wherein said light chain variable region comprises SEQ ID NO:10.

4. The isolated antibody according to claim 1 wherein said heavy chain variable region comprises SEQ ID NO:9 and said light chain variable region comprises SEQ ID NO:10.

5. The isolated antibody according to claim 1 wherein the heavy chain comprises SEQ ID NO:21 and the light chain comprises SEQ ID NO:22.

6. The isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:

a) a heavy chain variable region comprising:

i) a first CDR comprising SEQ ID NO:13;

ii) a second CDR comprising SEQ ID NO:14;

iii) a third CDR comprising SEQ ID NO:15; and

b) a light chain variable region comprising:

i) a first CDR comprising SEQ ID NO:16;

ii) a second CDR comprising SEQ ID NO:17;

iii) a third CDR comprising SEQ ID NO:18.

7. The isolated antibody according to claim 6 wherein said heavy chain variable region comprises SEQ ID NO:11.

8. The isolated antibody according to claim 6 wherein said light chain variable region comprises SEQ ID NO:12.

9. The isolated antibody according to claim 6 wherein said heavy chain variable region comprises SEQ ID NO:19 and said light chain variable region comprises SEQ ID NO:20.

10. The isolated antibody according to claim 6 wherein the heavy chain comprises SEQ ID NO:34 and the light chain comprises SEQ ID NO:35.

11. The isolated antibody according to claim 1 further comprising an Fc domain.

12. The isolated antibody according to claim 11 wherein said Fc domain is human.

Assignments (6)
CORRECTION AND RELEASE OF SECURITY AGREEMENT Recorded Jan 14, 2025
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 069895/0584 →
SECURITY INTEREST Recorded May 9, 2018
From: XOMA (US) LLC
To: SILICON VALLEY BANK
Reel/Frame 046115/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2012
From: ELIAS, KATHLEEN ANN; LANDES, GREGORY; SINGH, SHWETA; KORVER, WOUTER; WALLING-DRAKE, ANDREW; HAAK-FRENDSCHO, MARY; SNELL, GYORGY PAL
To: TAKEDA CALIFORNIA, INC.
Reel/Frame 028314/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2012
From: BHASKAR, VINAY
To: XOMA (US) LLC
Reel/Frame 028314/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2012
From: XOMA (US) LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 028314/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2012
From: TAKEDA CALIFORNIA, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 028314/0365 →